A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in
subjects with advanced hematological malignancies, and to further assess the safety and
tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to
select a dose for future studies.